The JPM Healthcare Conference of 2024 may not have witnessed a mega-merger announcement, but there is anticipation that the M&A market could pick up this year, with predictions that the economic headwinds of recent years could turn into tailwinds. The recent M&A Firepower report from EY, formerly known as Ernst & Young, has forecast a […]
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]
Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]
Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement 17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a […]
